As initial treatment—RITUXAN, with CVP chemotherapy, may be given to treat follicular lymphoma. These drugs work together in different ways to fight cancer. The goal in using this combination of drugs is to keep your cancer from getting worse.
In one study, patients who received RITUXAN+CVP chemotherapy spent 1 year longer without their cancer advancing (compared with patients who received CVP chemotherapy by itself). These results were from a clinical trial and may not be the same as what you experience.
You will have up to 8 cycles, or rounds, of treatment. Each cycle will last 21 days. Treatment occurs on the first day of each cycle and is followed by 20 days of rest and recovery. This means that most people will complete their treatment in about 6 months.
PATIENTS MAY RECEIVE FEWER THAN 8 CYCLES OF RITUXAN IN COMBINATION WITH CHEMOTHERAPY.
The most common side effects reported more often in patients receiving RITUXAN and CVP chemotherapy vs. CVP chemotherapy alone were infusion-related reactions, decreased white blood cell counts, rash, cough, flushing, shivering, itching, and chest tightness.
Your doctor may decide to prescribe RITUXAN as maintenance therapy if you achieve remission after using RITUXAN (rituximab) and chemotherapy as initial treatment. RITUXAN is prescribed alone, without chemotherapy, every 8 weeks for 12 doses during this phase of the journey. Your goal here is to help keep your disease in remission.
In one study of patients with follicular lymphoma who received RITUXAN maintenance therapy (after responding to initial RITUXAN therapy plus chemotherapy), patients cut the risk of their disease advancing by almost half (46%) compared with patients who did not receive additional treatment after initial therapy. These results were from a clinical trial and may not be the same as what you experience.
RITUXAN is given once every 8 weeks for 12 doses as maintenance therapy. Severe side effects reported were infections and decreased white blood cell counts.
Severe side effects reported were infections and decreased white blood cell counts. The most frequently reported side effect was infections.
RITUXAN is available by prescription only.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.